GlassScriptPhysician profile
Kazeen Nuri Abdullah
NPI 1790084929
$2,033.10
in general payments reported to CMS, 2019-2025
19 companies · $1,939 in 2025
The $1,939 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $93.79 · 2025: $1,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $325.96 | 2025 | |
| Amgen INC. | $263.81 | 2024-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $196.66 | 2025 | Lokelma, Farxiga |
| Abbott Laboratories | $167.96 | 2025 | Triclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $148.93 | 2025 | |
| Merck Sharp & Dohme LLC | $125.45 | 2024-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $119.47 | 2025 | |
| Philips North America LLC | $109.10 | 2025 | Ecc Solutions, Extended Holter, Mcot |
| Novo Nordisk INC | $100.11 | 2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.59 | 2025 | Lifevest |
| Boston Scientific Corporation | $86.80 | 2024-2025 | Bodyguardian, Watchman Flx |
| Glaxosmithkline, LLC. | $66.12 | 2025 | Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $49.43 | 2025 | Camzyos |
| Tactile Systems Technology INC | $39.28 | 2025 | Nimbl, Flexitouch Plus |
| Alnylam Pharmaceuticals INC. | $38.96 | 2025 | Onpattro |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $35.11 | 2025 | Nexletol |
| Bridgebio Pharma, INC. | $26.29 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $22.11 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $19.96 | 2025 | Optowire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kazeen Abdullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.